Trial Profile

Dose finding phase IIb study of Bavisant to evaluate its safety and efficacy in treatment of excessive daytime sleepiness (EDS) in parkinson's Disease (PD)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 27 Nov 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bavisant (Primary)
Indications Hypersomnia
Focus Therapeutic Use
Acronyms CASPAR
Sponsors BenevolentAI

Most Recent Events

09 Jul 2019 Status changed from recruiting to completed.
21 Jun 2019 This trial has been completed in Czech Republic.
15 Jun 2019 This trial has been completed in Germany, according to European Clinical Trials Database.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com